vs
Esquire Financial Holdings, Inc.（ESQ）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
Esquire Financial Holdings, Inc.的季度营收约是REGENXBIO Inc.的1.3倍（$40.5M vs $30.3M），Esquire Financial Holdings, Inc.净利率更高（30.2% vs -221.3%，领先251.5%），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs 15.0%）
Esquire Financial Holdings是一家总部位于美国的银行控股公司，提供全面的商业及零售银行服务，核心业务包含存款账户、企业贷款、按揭服务及财富管理解决方案，主要服务中小型企业、法律行业从业者及当地零售客户。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
ESQ vs RGNX — 直观对比
营收规模更大
ESQ
是对方的1.3倍
$30.3M
净利率更高
ESQ
高出251.5%
-221.3%
两年增速更快
RGNX
近两年复合增速
15.0%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $40.5M | $30.3M |
| 净利润 | $12.2M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | — | -190.0% |
| 净利率 | 30.2% | -221.3% |
| 营收同比 | — | 43.0% |
| 净利润同比 | 7.0% | -31.2% |
| 每股收益（稀释后） | $1.40 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ESQRGNX
| Q1 26 | $40.5M | — | ||
| Q4 25 | $39.4M | $30.3M | ||
| Q3 25 | $37.6M | $29.7M | ||
| Q2 25 | $35.8M | $21.4M | ||
| Q1 25 | $33.8M | $89.0M | ||
| Q4 24 | $33.1M | $21.2M | ||
| Q3 24 | $31.9M | $24.2M | ||
| Q2 24 | $30.6M | $22.3M |
净利润ESQRGNX
| Q1 26 | $12.2M | — | ||
| Q4 25 | $13.5M | $-67.1M | ||
| Q3 25 | $14.1M | $-61.9M | ||
| Q2 25 | $11.9M | $-70.9M | ||
| Q1 25 | $11.4M | $6.1M | ||
| Q4 24 | $11.8M | $-51.2M | ||
| Q3 24 | $11.4M | $-59.6M | ||
| Q2 24 | $10.5M | $-53.0M |
毛利率ESQRGNX
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% |
营业利润率ESQRGNX
| Q1 26 | — | — | ||
| Q4 25 | 44.3% | -190.0% | ||
| Q3 25 | 46.5% | -176.3% | ||
| Q2 25 | 42.5% | -296.3% | ||
| Q1 25 | 45.9% | 13.6% | ||
| Q4 24 | 47.4% | -242.1% | ||
| Q3 24 | 48.8% | -256.6% | ||
| Q2 24 | 46.9% | -251.3% |
净利率ESQRGNX
| Q1 26 | 30.2% | — | ||
| Q4 25 | 34.2% | -221.3% | ||
| Q3 25 | 37.4% | -208.3% | ||
| Q2 25 | 33.2% | -331.8% | ||
| Q1 25 | 33.8% | 6.8% | ||
| Q4 24 | 35.6% | -241.3% | ||
| Q3 24 | 35.6% | -246.3% | ||
| Q2 24 | 34.3% | -237.7% |
每股收益（稀释后）ESQRGNX
| Q1 26 | $1.40 | — | ||
| Q4 25 | $1.54 | $-1.30 | ||
| Q3 25 | $1.62 | $-1.20 | ||
| Q2 25 | $1.38 | $-1.38 | ||
| Q1 25 | $1.33 | $0.12 | ||
| Q4 24 | $1.35 | $-0.99 | ||
| Q3 24 | $1.34 | $-1.17 | ||
| Q2 24 | $1.25 | $-1.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $222.2M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $301.3M | $102.7M |
| 总资产 | $2.4B | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ESQRGNX
| Q1 26 | $222.2M | — | ||
| Q4 25 | $235.9M | $230.1M | ||
| Q3 25 | $240.8M | $274.2M | ||
| Q2 25 | $163.0M | $323.3M | ||
| Q1 25 | $173.0M | $267.9M | ||
| Q4 24 | $126.3M | $234.7M | ||
| Q3 24 | $147.7M | $255.5M | ||
| Q2 24 | $152.7M | $290.4M |
股东权益ESQRGNX
| Q1 26 | $301.3M | — | ||
| Q4 25 | $289.6M | $102.7M | ||
| Q3 25 | $279.2M | $161.5M | ||
| Q2 25 | $263.6M | $213.7M | ||
| Q1 25 | $250.7M | $274.2M | ||
| Q4 24 | $237.1M | $259.7M | ||
| Q3 24 | $232.6M | $301.4M | ||
| Q2 24 | $217.4M | $348.3M |
总资产ESQRGNX
| Q1 26 | $2.4B | — | ||
| Q4 25 | $2.4B | $453.0M | ||
| Q3 25 | $2.2B | $525.2M | ||
| Q2 25 | $2.1B | $581.0M | ||
| Q1 25 | $2.0B | $490.9M | ||
| Q4 24 | $1.9B | $466.0M | ||
| Q3 24 | $1.8B | $519.1M | ||
| Q2 24 | $1.7B | $569.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流ESQRGNX
| Q1 26 | — | — | ||
| Q4 25 | $59.8M | $-52.3M | ||
| Q3 25 | $16.8M | $-56.0M | ||
| Q2 25 | $10.5M | $-49.3M | ||
| Q1 25 | $15.8M | $33.6M | ||
| Q4 24 | $42.2M | $-31.6M | ||
| Q3 24 | $10.5M | $-40.5M | ||
| Q2 24 | $7.2M | $-45.5M |
自由现金流ESQRGNX
| Q1 26 | — | — | ||
| Q4 25 | $56.7M | $-52.8M | ||
| Q3 25 | $16.2M | $-56.5M | ||
| Q2 25 | $9.3M | $-49.7M | ||
| Q1 25 | $14.7M | $32.6M | ||
| Q4 24 | $41.5M | $-32.7M | ||
| Q3 24 | $10.5M | $-40.9M | ||
| Q2 24 | $6.9M | $-46.0M |
自由现金流率ESQRGNX
| Q1 26 | — | — | ||
| Q4 25 | 143.9% | -174.0% | ||
| Q3 25 | 43.2% | -189.9% | ||
| Q2 25 | 26.0% | -232.8% | ||
| Q1 25 | 43.4% | 36.6% | ||
| Q4 24 | 125.5% | -154.2% | ||
| Q3 24 | 32.8% | -168.9% | ||
| Q2 24 | 22.5% | -206.2% |
资本支出强度ESQRGNX
| Q1 26 | — | — | ||
| Q4 25 | 8.0% | 1.7% | ||
| Q3 25 | 1.3% | 1.7% | ||
| Q2 25 | 3.2% | 1.8% | ||
| Q1 25 | 3.4% | 1.2% | ||
| Q4 24 | 2.2% | 5.1% | ||
| Q3 24 | 0.2% | 1.3% | ||
| Q2 24 | 1.1% | 2.1% |
现金转化率ESQRGNX
| Q1 26 | — | — | ||
| Q4 25 | 4.44× | — | ||
| Q3 25 | 1.19× | — | ||
| Q2 25 | 0.88× | — | ||
| Q1 25 | 1.39× | 5.53× | ||
| Q4 24 | 3.59× | — | ||
| Q3 24 | 0.93× | — | ||
| Q2 24 | 0.69× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ESQ
| Net Interest Income | $34.0M | 84% |
| Noninterest Income | $6.5M | 16% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
